Zenas BioPharma, Inc. ("Zenas" or the "Company") , a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative ...

PROpel (NCT03732820) was a positive phase 3 trial that demonstrated a clinically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

Q3 revenue and core EPS beat estimates AstraZeneca announces $3.5 billion US investment CEO says growth looks set to continue through 2025 Shares down as market focuses on co's China issues ...

The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...